Biotech firms are working on developing weight-loss drugs for dogs, similar to Ozempic, to combat obesity that affects over half of pet dogs. Ozempic and Wegovy contain semaglutide, which functions as a GLP-1 receptor agonist to suppress appetite by controlling blood sugar. Since these chemicals do not work in dogs, alternatives known as GLP-1 mimics are being researched. Okava, in partnership with Vivani Medical, is trialing an implant using the alternative GLP-1 mimic OKV-119. This implant is approximately the size of a tracking chip and would provide a steady release of weight-loss drugs every six months.
Scientists are developing a weight-loss implant for dogs that mimics the effects of Ozempic's active ingredient, aiming to help them slim down and reduce obesity-related health risks.
Okava's new implant, OKV-119, will be delivered every six months, designed to release weight-loss drugs that suppress appetite and help prevent obesity in pets.
Collection
[
|
...
]